Company profile for RheumaGen

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

RheumaGen is pioneering a new class of cell and gene therapies aimed at curing autoimmune diseases by addressing their root cause. The company focuses on precisely editing the human leukocyte antigen (HLA) gene—the key regulator of immune response—to stop the immune system from attacking healthy cells. By modifying harmful HLA alleles to mirror those of individuals resistant to specific autoimmune diseases, RheumaGen’s t...
RheumaGen is pioneering a new class of cell and gene therapies aimed at curing autoimmune diseases by addressing their root cause. The company focuses on precisely editing the human leukocyte antigen (HLA) gene—the key regulator of immune response—to stop the immune system from attacking healthy cells. By modifying harmful HLA alleles to mirror those of individuals resistant to specific autoimmune diseases, RheumaGen’s therapies prevent abnormal T-cell activation, halting tissue damage and stopping the autoimmune process entirely.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
200 Quebec St, 205, Denver, Colorado 80230, US
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/rheumagen-and-sivec-biotechnologies-announce-cgt-partnership-and-in-vivo-program-to-cure-common-autoimmune-diseases-302576335.html

PR NEWSWIRE
07 Oct 2025

https://www.prnewswire.com/news-releases/rheumagen-announces-oral-presentation-on-hla-gene-editing-preclinical-data-for-lead-autoimmune-disease-program-at-acr-convergence-2025-302571690.html

PR NEWSWIRE
01 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty